Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Illinois Wellness Insider.
Press releases published on July 29, 2025

Telix H1 2025 Results: Investor Webcast Notification
MELBOURNE, Australia and INDIANAPOLIS, July 30, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today advises that it will release its financial results for the half-year ended 30 June 2025 on Thursday 21 August 2025 …

Rakovina Therapeutics Announces Stock Option Grants
VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (FSE: 7JO0) (the “Company” or “Rakovina”), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug …

Amedisys Reports Second Quarter 2025 Financial Results
BATON ROUGE, La., July 29, 2025 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and six-month periods ended June 30, 2025. Three-Month Periods Ended June 30, 2025 and 2024 Net service revenue increased $ …

Informations sur le nombre total de droits de vote et d'actions
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 29 juillet 2025, 22:45h CET / 16:45h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des …

Information on the total number of voting rights and shares
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), July 29, 2025, 10:45 pm CET / 4:45 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, …

Dr. Sam Speron Provides Insight Into Bunny Lines and Advances in Natural Facial Rejuvenation
Dr. Sam Speron Provides Insight Into Bunny Lines and Advances in Natural Facial Rejuvenation CHICAGO, IL, UNITED STATES, July 29, 2025 /EINPresswire.com/ -- Dr. Sam Speron, a leading plastic and reconstructive surgeon specializing in cosmetic …

Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025
Nyxoah to Release Second Quarter 2025 Financial Results on August 18, 2025 Mont-Saint-Guibert, Belgium – Tuesday July 29, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), that develops breakthrough …

Nyxoah Publiera ses Résultats Financiers du Second Trimestre 2025 le 18 Août 2025
Nyxoah Publiera ses Résultats Financiers du Second Trimestre 2025 le 18 Août 2025 Mont-Saint-Guibert, Belgique – Mardi 29 juillet 2025, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (« Nyxoah » ou la « Société »), une société de …

Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution
WILMINGTON, Del., July 29, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), a wholly owned subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) and a leading AI-powered physician- …

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025
SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual …

100th Fisher House Dedicated at Lovell Federal Health Care Center
North Chicago, IL, July 29, 2025 (GLOBE NEWSWIRE) -- A new Fisher House was dedicated at the Captain James A. Lovell Federal Health Care Center (Lovell FHCC) by Lovell FHCC Director Dr. Robert Buckley, Deputy Director, Commanding Officer NMRTC Great Lakes …

DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
Châtillon, France, July 29, 2025 DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage …

DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation
Châtillon, France, le 29 juillet 2025 DBV Technologies publie son Rapport Financier Semestriel 2025 ― Modalités de mise à disposition ou de consultation DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société biopharmaceutique …

Bioventus to Report Second Quarter of Fiscal Year 2025 Financial Results on August 6, 2025
DURHAM, N.C., July 29, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the second quarter of fiscal year 2025 …

Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference
ALACHUA, Fla. and TAMPA, Fla., July 29, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that management will …

DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
Châtillon, France, July 29, 2025 DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, …

DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025
Châtillon, France, le 29 juillet 2025 DBV Technologies publie ses résultats financiers du 2ème trimestre et 1er semestre 2025 DBV Technologies (Euronext : DBV - ISIN : FR0010417345 - Nasdaq Stock Market : DBVT-CUSIP : 23306J309), société biopharmaceutique …

Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004)
– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring 30mg onvansertib dose arm vs. control arm – – Onvansertib …

Teladoc Health Reports Second Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended June 30, 2025 (“Second Quarter 2025”). Unless otherwise noted, percentage and …

NeuroPace to Report Second Quarter 2025 Financial Results on August 12, 2025
MOUNTAIN VIEW, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the second quarter of …